153 related articles for article (PubMed ID: 38059274)
1. Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis.
Sherman MA; Yang Q; Gutierrez-Alamillo L; Pak K; Flegel WA; Mammen AL; Rider LG; Casciola-Rosen LA;
Arthritis Rheumatol; 2024 Apr; 76(4):631-637. PubMed ID: 38059274
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies Recognizing Specificity Protein 4 Co-occur With Anti-Transcription Intermediary Factor 1 and Are Associated With Distinct Clinical Features and Immunogenetic Risk Factors in Juvenile Myositis.
Sherman MA; Pak K; Pinal-Fernandez I; Flegel WA; Targoff IN; Miller FW; Rider LG; Mammen AL;
Arthritis Rheumatol; 2023 Sep; 75(9):1668-1677. PubMed ID: 36996276
[TBL] [Abstract][Full Text] [Related]
3. Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis.
Fiorentino D; Mecoli CA; Igusa T; Albayda J; Paik JJ; Tiniakou E; Adler B; Mammen AL; Shah AA; Rosen A; Christopher-Stine L; Casciola-Rosen L
Arthritis Rheumatol; 2023 Jul; 75(7):1238-1245. PubMed ID: 36762496
[TBL] [Abstract][Full Text] [Related]
4. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies.
Hosono Y; Sie B; Pinal-Fernandez I; Pak K; Mecoli CA; Casal-Dominguez M; Warner BM; Kaplan MJ; Albayda J; Danoff S; Lloyd TE; Paik JJ; Tiniakou E; Aggarwal R; Oddis CV; Moghadam-Kia S; Carmona-Rivera C; Milisenda JC; Grau-Junyent JM; Selva-O'Callaghan A; Christopher-Stine L; Larman HB; Mammen AL
Ann Rheum Dis; 2023 Feb; 82(2):246-252. PubMed ID: 36008132
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of anti-transcription intermediary factor 1γ (TIF1γ)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1γ expression in tumors in the pathogenesis of cancer-associated dermatomyositis.
Motegi SI; Sekiguchi A; Ikeuchi H; Sakairi T; Ogawa H; Fujii T; Sohda M; Yajima T; Ida S; Takayasu Y; Shimoda Y; Hiromura K; Saeki H; Shirabe K; Chikamatsu K; Yokoo H; Oyama T; Ishikawa O
J Dermatol; 2020 Dec; 47(12):1395-1402. PubMed ID: 32734678
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.
Kotobuki Y; Tonomura K; Fujimoto M
Immunol Med; 2021 Mar; 44(1):23-29. PubMed ID: 32649853
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence.
Fiorentino DF; Mecoli CA; Rosen MC; Chung LS; Christopher-Stine L; Rosen A; Casciola-Rosen L
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 35040440
[TBL] [Abstract][Full Text] [Related]
8. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.
Aussy A; Fréret M; Gallay L; Bessis D; Vincent T; Jullien D; Drouot L; Jouen F; Joly P; Marie I; Meyer A; Sibilia J; Bader-Meunier B; Hachulla E; Hamidou M; Huë S; Charuel JL; Fabien N; Viailly PJ; Allenbach Y; Benveniste O; Cordel N; Boyer O;
Arthritis Rheumatol; 2019 Aug; 71(8):1360-1370. PubMed ID: 30896088
[TBL] [Abstract][Full Text] [Related]
9. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
[TBL] [Abstract][Full Text] [Related]
10. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap.
Wedderburn LR; McHugh NJ; Chinoy H; Cooper RG; Salway F; Ollier WE; McCann LJ; Varsani H; Dunphy J; North J; Davidson JE;
Rheumatology (Oxford); 2007 Dec; 46(12):1786-91. PubMed ID: 18003662
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.
Gunawardena H; Wedderburn LR; Chinoy H; Betteridge ZE; North J; Ollier WE; Cooper RG; Oddis CV; Ramanan AV; Davidson JE; McHugh NJ;
Arthritis Rheum; 2009 Jun; 60(6):1807-14. PubMed ID: 19479859
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis.
Zhang L; Yang H; Yang H; Liu H; Tian X; Jiang W; Peng Q; Wang G; Lu X
Semin Arthritis Rheum; 2022 Aug; 55():152011. PubMed ID: 35489170
[TBL] [Abstract][Full Text] [Related]
13. A Case of Dermatomyositis Along with Esophageal Cancer and Screening of Serum Transcriptional Intermediary Factor 1 Gamma Antibodies in Various Cancer Patients.
Sumazaki M; Kaneko K; Ito M; Oshima Y; Saito F; Ogata H; Shibuya K; Shimada H
Am J Case Rep; 2020 Apr; 21():e922004. PubMed ID: 32312948
[TBL] [Abstract][Full Text] [Related]
14. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
15. Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature.
Ono R; Kumagae T; Igasaki M; Murata T; Yoshizawa M; Kitagawa I
J Med Case Rep; 2021 Mar; 15(1):142. PubMed ID: 33745453
[TBL] [Abstract][Full Text] [Related]
16. Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients.
Kang EH; Go DJ; Mimori T; Lee SJ; Kwon HM; Park JW; Park MH; Song EY; Ha YJ; Lee EY; Lee YJ; Lee EB; Song YW
Semin Arthritis Rheum; 2019 Oct; 49(2):283-287. PubMed ID: 30952422
[TBL] [Abstract][Full Text] [Related]
17. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians.
Mamyrova G; O'Hanlon TP; Monroe JB; Carrick DM; Malley JD; Adams S; Reed AM; Shamim EA; James-Newton L; Miller FW; Rider LG;
Arthritis Rheum; 2006 Dec; 54(12):3979-87. PubMed ID: 17133612
[TBL] [Abstract][Full Text] [Related]
18. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
Fujimoto M; Murakami A; Kurei S; Okiyama N; Kawakami A; Mishima M; Sato S; Seishima M; Suda T; Mimori T; Takehara K; Kuwana M
J Dermatol Sci; 2016 Dec; 84(3):272-281. PubMed ID: 27693019
[TBL] [Abstract][Full Text] [Related]
19. Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies.
Leclair V; Galindo-Feria AS; Rothwell S; Kryštůfková O; Zargar SS; Mann H; Diederichsen LP; Andersson H; Klein M; Tansley S; Rönnblom L; Lindblad-Toh K; Syvänen AC; Wahren-Herlenius M; Sandling JK; ; McHugh N; Lamb JA; Vencovský J; Chinoy H; Holmqvist M; Bianchi M; Padyukov L; Lundberg IE; Diaz-Gallo LM
EBioMedicine; 2023 Oct; 96():104804. PubMed ID: 37769433
[TBL] [Abstract][Full Text] [Related]
20. Genetic association of HLA-DRB1 multiple polymorphisms with dermatomyositis in Chinese population.
Lin JM; Zhang YB; Peng QL; Yang HB; Shi JL; Gu ML; Zhao WM; Wang GC
HLA; 2017 Dec; 90(6):354-359. PubMed ID: 29106035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
